Nordic Bioscience receives Letter of Support from the FDA for the PRO-C3 biomarker in tumor fibrosis
Nordic Bioscience receives Letter of Support from the U.S. Food and Drug Administration (FDA) for further study of the PRO-C3 biomarker assay in tumor fibrosis studies
- Paves way for further testing of the PRO-C3 biomarker assay, which identifies patients with hard to treat ‘fibrotic’ tumors, in further clinical trials
- US FDA recognizes need for a blood test for cancer aggressiveness which would be ‘potentially more accessible’ for patients than today’s tumor biopsy approach
- Potential to enable more targeted therapy and bring treatments to market faster and at a lower cost
